Complement C5 Targeting Strategies: Mechanisms and Therapeutic Applications

Introduction

The complement system is a critical component of innate immunity, responsible for pathogen defense, immune regulation, and elimination of abnormal cells. As the terminal effector molecule of the complement cascade, Complement C5 plays a central role by generating two key fragments: C5a, a powerful inflammatory mediator, and C5b, the initiator of membrane attack complex (MAC) formation.

Due to its involvement in excessive immune activation and inflammatory diseases, C5 has become an important therapeutic target. Recent advances in antibody discovery and aptamer development have enabled new strategies for selectively blocking C5 activity.

C5 Activation and Biological Functions

1. Structural Basis of C5 Activation

C5 is a plasma glycoprotein mainly produced by hepatocytes and consists of α- and β-chains connected through disulfide bonds. All three complement activation pathways ultimately generate C5 convertase, which cleaves C5 at the Arg751–Leu752 site to produce C5a and C5b.

Key features of C5 activation include:

• The cleavage site is structurally hidden in inactive C5 and becomes accessible after interaction with C5 convertase.
• Unlike complement C3, C5 lacks a thioester bond and requires enzymatic positioning for activation.
• C5a and C5b perform distinct immune functions after cleavage.

2. Functions of C5a and C5b

C5a: A potent inflammatory mediator

C5a binds to receptors such as C5aR1 and C5L2 to regulate immune responses. Its major functions include:

• Recruiting neutrophils, monocytes, and macrophages to inflammatory sites
• Activating immune cells and promoting cytokine release
• Inducing mast cell and basophil degranulation, increasing vascular permeability

While essential for immune defense, excessive C5a signaling contributes to chronic inflammation and autoimmune pathology.

C5b: Initiator of membrane attack complex formation

C5b initiates sequential recruitment of C6, C7, C8, and C9 to form the MAC. This membrane pore structure enables immune-mediated destruction of:

• Bacteria
• Virus-infected cells
• Abnormal or damaged cells

However, uncontrolled MAC activation can also damage healthy tissues.

C5 as a Therapeutic Target in Immune Diseases

Dysregulated C5 activation contributes to multiple inflammatory and autoimmune disorders.

Examples include:

• Paroxysmal nocturnal hemoglobinuria (PNH): Loss of complement regulatory proteins leads to uncontrolled MAC formation and red blood cell destruction.
• Atypical hemolytic uremic syndrome (aHUS): Abnormal complement regulation causes endothelial injury and microvascular thrombosis.
• Autoimmune inflammatory diseases: C5 inhibition has shown protective effects in several preclinical disease models.

These findings have supported the development of C5-targeted therapies.

FDA-Approved C5 Inhibitors

1. C5 Antibody Therapies

Monoclonal antibodies such as Eculizumab and Ravulizumab directly bind C5 and prevent cleavage by C5 convertase.

Their therapeutic effects include:

• Blocking C5a-mediated inflammatory signaling
• Preventing C5b-driven MAC formation
• Reducing complement-mediated tissue damage

The development of these antibodies has been supported by advanced antibody discovery technologies, including phage display screening for high-affinity binders.

2. Aptamer-Based C5 Inhibition

Unlike antibody therapies, Avacincaptad pegol is an RNA aptamer drug generated through aptamer selection from randomized nucleic acid libraries.

This C5-targeting aptamer:

• Binds C5 and prevents cleavage
• Inhibits MAC formation
• Maintains upstream complement functions involved in immune regulation

It has been approved for the treatment of geographic atrophy, demonstrating the clinical potential of aptamer-based complement modulation.

Conclusion

Complement C5 serves as a key regulatory point within the complement cascade, controlling inflammatory signaling through C5a and target-cell elimination through MAC formation. Excessive C5 activation contributes to multiple immune-mediated diseases, making it an attractive therapeutic target.

Both antibody-based C5 inhibitors and aptamer-based C5 targeting strategies have demonstrated significant clinical value. Continued advances in antibody discovery, phage display technology, and aptamer selection platforms will further expand opportunities for developing next-generation complement therapeutics.

To support drug discovery and mechanistic research targeting C5, Alpha Lifetech has accumulated extensive technical expertise and can provide high-purity, high-activity C5 recombinant proteins to meet needs ranging from molecular interaction to cellular functional validation. In addition, the company has established a mature Peptide Library Screening and Phage Display Technology Platform that can efficiently screen for specific antibodies, peptides, and alternative scaffold molecules against C5 or its cleavage interface, facilitating the development of next-generation complement inhibitors. Leveraging these specialized capabilities, Alpha Lifetech is committed to providing a one-stop solution from tools to screening for translational medicine research in the complement field.